What is ASND's P/E ratio?

ASCENDIS PHARMA AS (ASND) currently trades at a P/E ratio of 25.74.

ASCENDIS PHARMA AS reports a Return on Equity (ROE) of 103.71%.

What is ASND's dividend yield?

ASCENDIS PHARMA AS offers a dividend yield of 0.00%.

What is ASND's Quality Score?

Our AI rates ASND's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ASND?

Our AI Timing Score for ASND is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ASND belong to?

ASCENDIS PHARMA AS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

ASND (NASDAQ) Stock Analysis | ASCENDIS PHARMA AS

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ASND AI Analysis Summary

Our AI summary for ASND: ASCENDIS PHARMA AS (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 25.74, ROE of 103.71%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ASND

ASCENDIS PHARMA AS

US:NASDAQ STOCK Healthcare >> Biotechnology News 93

USD 243.91

-7.16 (-2.85%) Day Change

Watchlist Portfolio Compare Chart

25.74

P/E

1.84

D/E

103.7%

ROE

25.3%

ROA

0.00%

Div Yield

ASCENDIS PHARMA AS
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 243.91 Price -7.16 (-2.85%) Day Change	NEWS SCORE: 93

ASND, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

47%

In Recommendations?	In "Invest - GROWTH" Section
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	93
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	243.91
PBV / Sector	33.71 / 5.20
Earning Per Share	7.50

PE / Sector	25.74 / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	129.55 M GREAT
Average 1W Daily Value	120.20 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	58.40 / 98.71 GREAT
NPM Average (%) / Sector	-279.48 / -1,721.76
NPM Change Average (%) / Sector	-120.13 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	25.26 / 27.02 GREAT
ROA Average (%) / Sector	-27.09 / -368.17
ROA Change Average (%) / Sector	-83.44 / 5,404.12
ROE (%) / Sector	103.71 / 3.47 GREAT
ROE Average (%) / Sector	140.99 / 6.51 GREAT
ROE Change Average (%) / Sector	-81.57 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:30
Symbol	ASND
Name	ASCENDIS PHARMA AS
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	65.59 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	16,468.39 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900

Phone: 45 70 22 22 44

Website: https://ascendispharma.com

Employees: 1,189

Sector: Healthcare >> Biotechnology

Description: Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.